BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 37947595)

  • 1. HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer.
    Majumder A
    Cells; 2023 Oct; 12(21):. PubMed ID: 37947595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway.
    Sakai K; Yokote H; Murakami-Murofushi K; Tamura T; Saijo N; Nishio K
    Cancer Sci; 2007 Sep; 98(9):1498-503. PubMed ID: 17627612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer models.
    Xia W; Petricoin EF; Zhao S; Liu L; Osada T; Cheng Q; Wulfkuhle JD; Gwin WR; Yang X; Gallagher RI; Bacus S; Lyerly HK; Spector NL
    Breast Cancer Res; 2013; 15(5):R85. PubMed ID: 24044505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropeptide bombesin receptor activation stimulates growth of lung cancer cells through HER3 with a MAPK-dependent mechanism.
    Lee L; Ramos-Alvarez I; Moody TW; Mantey SA; Jensen RT
    Biochim Biophys Acta Mol Cell Res; 2020 Apr; 1867(4):118625. PubMed ID: 31862538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HER3 for cancer treatment: a new horizon for an old target.
    Uliano J; Corvaja C; Curigliano G; Tarantino P
    ESMO Open; 2023 Feb; 8(1):100790. PubMed ID: 36764093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy.
    Iida M; Brand TM; Starr MM; Huppert EJ; Luthar N; Bahrar H; Coan JP; Pearson HE; Salgia R; Wheeler DL
    Mol Cancer; 2014 Oct; 13():242. PubMed ID: 25344208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies.
    Udagawa H; Nilsson MB; Robichaux JP; He J; Poteete A; Jiang H; Heeke S; Elamin YY; Shibata Y; Matsumoto S; Yoh K; Okazaki S; Masuko T; Odintsov I; Somwar R; Ladanyi M; Goto K; Heymach JV
    J Thorac Oncol; 2024 Jan; 19(1):106-118. PubMed ID: 37678511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the HER3 pseudokinase domain with small molecule inhibitors.
    Colomba A; Claus J; Gao F; George R; Fornili A; Cameron AJM
    Methods Enzymol; 2022; 667():455-505. PubMed ID: 35525551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.
    Kang JC; Poovassery JS; Bansal P; You S; Manjarres IM; Ober RJ; Ward ES
    MAbs; 2014; 6(2):340-53. PubMed ID: 24492289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathways: HER3 targeted therapy.
    Gala K; Chandarlapaty S
    Clin Cancer Res; 2014 Mar; 20(6):1410-6. PubMed ID: 24520092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Potent HER3 Monoclonal Antibody That Blocks Both Ligand-Dependent and -Independent Activities: Differential Impacts of PTEN Status on Tumor Response.
    Xiao Z; Carrasco RA; Schifferli K; Kinneer K; Tammali R; Chen H; Rothstein R; Wetzel L; Yang C; Chowdhury P; Tsui P; Steiner P; Jallal B; Herbst R; Hollingsworth RE; Tice DA
    Mol Cancer Ther; 2016 Apr; 15(4):689-701. PubMed ID: 26880266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung Cancer.
    Yonesaka K; Tanizaki J; Maenishi O; Haratani K; Kawakami H; Tanaka K; Hayashi H; Sakai K; Chiba Y; Tsuya A; Goto H; Otsuka E; Okida H; Kobayashi M; Yoshimoto R; Funabashi M; Hashimoto Y; Hirotani K; Kagari T; Nishio K; Nakagawa K
    Clin Cancer Res; 2022 Jan; 28(2):390-403. PubMed ID: 34921025
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HER3/ErbB3, an emerging cancer therapeutic target.
    Zhang N; Chang Y; Rios A; An Z
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):39-48. PubMed ID: 26496898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells.
    Choi BK; Fan X; Deng H; Zhang N; An Z
    Cancer Med; 2012 Aug; 1(1):28-38. PubMed ID: 23342251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade.
    Geuijen CAW; De Nardis C; Maussang D; Rovers E; Gallenne T; Hendriks LJA; Visser T; Nijhuis R; Logtenberg T; de Kruif J; Gros P; Throsby M
    Cancer Cell; 2018 May; 33(5):922-936.e10. PubMed ID: 29763625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HER3 monoclonal antibody patritumab sensitizes refractory non-small cell lung cancer to the epidermal growth factor receptor inhibitor erlotinib.
    Yonesaka K; Hirotani K; Kawakami H; Takeda M; Kaneda H; Sakai K; Okamoto I; Nishio K; Jänne PA; Nakagawa K
    Oncogene; 2016 Feb; 35(7):878-86. PubMed ID: 25961915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
    Sergina NV; Rausch M; Wang D; Blair J; Hann B; Shokat KM; Moasser MM
    Nature; 2007 Jan; 445(7126):437-41. PubMed ID: 17206155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.